SP Scientific, and Praxair Inc., headquartered in Danbury, CT, are pleased to
announce the expansion of their collaborative relationship to commercialize
Praxair's ControLyo™ Nucleation on Demand Technology.
The original agreement, signed in October 2010, gave SP Scientific the
exclusive, global rights to commercialize the technology on Development
Lyophilizers <1.0 m. The Praxair ControLyo™ Technology was implemented on SP
Scientific's Lyostar 3 Freeze Dryer in December 2010. The expansion of the
agreement allows SP Scientific to also equip its clinical, pilot and production
dryers (Benchmark series and Hull Production Dryers) with the ControLyo™
Technology. Additionally, the agreement calls for the transfer of technology to
allow SP Scientific to retrofit existing Pilot and Production units in the
field, regardless of the original manufacturer.
"This is a major step in SP's strategy of technology leadership in
lyophilization," states Chuck Grant, CEO for SP Scientific. "Given
the ability to offer the technology from development through scale-up to
production, SP Scientific is ideally positioned to be the supplier of choice
for ControLyo™ Technology."
"Praxair is pleased to extend our existing agreement to cover the full
range of lyophilizers offered to the industry by SP Scientific, " said
Rich Jarrett, Global Director of Marketing and Business Development for
Praxair. "Praxair's ControLyo™ Technology has seen quick industry adoption
with SP Scientific's Lyostar 3 FreezeDryer and we look forward to providing the
industry with nucleation control at all production levels."
ControLyo™ Technology offers many benefits to the pharmaceutical industry
including: vial-to-vial uniformity, reduced cycle times, reduced protein
aggregation and better conformance to the Food and Drug Administration's
Process Analytical Technology (PAT) initiative.
No comments:
Post a Comment